These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 34501738)

  • 21. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
    Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
    PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
    Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
    PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
    Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
    Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis.
    Lim PC; Wong KL; Rajah R; Chong MF; Chow TS; Subramaniam S; Lee CY
    Daru; 2022 Jun; 30(1):211-228. PubMed ID: 35084705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.
    Yu SY; Koh DH; Choi M; Ryoo S; Huh K; Yeom JS; Yoon YK
    Emerg Microbes Infect; 2022 Dec; 11(1):1154-1165. PubMed ID: 35343397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
    JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis.
    Nugroho CW; Suryantoro SD; Yuliasih Y; Rosyid AN; Asmarawati TP; Andrianto L; Setiawan HW; Mahdi BA; Windradi C; Agustin ED; Fajar JK
    F1000Res; 2021; 10():73. PubMed ID: 33763201
    [No Abstract]   [Full Text] [Related]  

  • 31. Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.
    Peng J; She X; Mei H; Zheng H; Fu M; Liang G; Wang Q; Liu W
    Aging (Albany NY); 2022 Jan; 14(2):557-571. PubMed ID: 35038318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials.
    Selvaraj V; Khan MS; Bavishi C; Dapaah-Afriyie K; Finn A; Lal A; Mylonakis E
    Lung; 2021 Jun; 199(3):239-248. PubMed ID: 34050796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
    Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
    Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.
    Khan FA; Stewart I; Fabbri L; Moss S; Robinson K; Smyth AR; Jenkins G
    Thorax; 2021 Sep; 76(9):907-919. PubMed ID: 33579777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of subcutaneous vs. intravenous tocilizumab in patients with severe COVID-19: a systematic review.
    Li Y; Li X; Zheng X
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1523-1530. PubMed ID: 38926166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of tocilizumab in COVID-19: A review of the current evidence.
    Alam W; Bizri AR
    Sci Prog; 2021; 104(3):368504211030372. PubMed ID: 34236264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: A systematic review and meta-analysis.
    Zhang J; Chen C; Yang Y; Yang J
    Medicine (Baltimore); 2022 Mar; 101(9):e28967. PubMed ID: 35244063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.
    Wei Q; Lin H; Wei RG; Chen N; He F; Zou DH; Wei JR
    Infect Dis Poverty; 2021 May; 10(1):71. PubMed ID: 34001244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis.
    Aziz M; Haghbin H; Abu Sitta E; Nawras Y; Fatima R; Sharma S; Lee-Smith W; Duggan J; Kammeyer JA; Hanrahan J; Assaly R
    J Med Virol; 2021 Mar; 93(3):1620-1630. PubMed ID: 32918755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.